Edition:
United Kingdom

Affimed NV (AFMD.OQ)

AFMD.OQ on NASDAQ Stock Exchange Global Market

4.35USD
18 Sep 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$4.35
Open
--
Day's High
--
Day's Low
--
Volume
100
Avg. Vol
176,382
52-wk High
$7.35
52-wk Low
$1.17

Chart for

About

Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its... (more)

Overall

Beta: --
Market Cap(Mil.): $96.98
Shares Outstanding(Mil.): 43.26
Dividend: --
Yield (%): --

Financials

  AFMD.OQ Industry Sector
P/E (TTM): -- 85.68 32.76
EPS (TTM): -0.99 -- --
ROI: -62.77 1.78 14.61
ROE: -67.79 3.29 16.33

BRIEF-Affimed To Collaborate With Genentech To Develop Novel Nk Cell Engager-Based Immunotherapeutics

* AFFIMED ANNOUNCES COLLABORATION WITH GENENTECH TO DEVELOP NOVEL NK CELL ENGAGER-BASED IMMUNOTHERAPEUTICS FOR MULTIPLE CANCER TARGETS

27 Aug 2018

Earnings vs. Estimates